Compare Biogen Inc (BIIB) vs Cincinnati Financial Corporation (CINF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Cincinnati Financial Corporation — how do they compare? Biogen Inc trades at $208.51 (market cap $30.13B), while Cincinnati Financial Corporation trades at $172.42 (market cap $26.58B). The key difference: Biogen Inc and Cincinnati Financial Corporation are close in size by market cap, and Cincinnati Financial Corporation pays a 2.17% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | CINF | |
|---|---|---|
Market Cap | $30.13B | $26.58B |
Sector | Health | Financials |
52-Week High | $216.63 | $192.03 |
52-Week Low | $128.93 | $149.79 |
Enterprise Value | $37.20B | $25.71B |
Dividend Yield | — | 2.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.
Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.
Cincinnati Financial (CINF) trades at $172.87, down 0.57% on the day, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 earnings miss ($1.43 vs. $1.84 expected) but maintains robust revenue growth and profitability with a 23.84% net income margin. Cash flow trends show improvement, with 2025 net cash flow reaching $448 million. Analyst consensus remains positive with a $195 price target, though technical indicators suggest near-term pressure.
CINF presents a value opportunity with attractive valuation metrics (P/E 8.18, P/B 1.59) and consistent dividend growth. Key risks include catastrophe losses impacting underwriting results and commercial lines performance. The stock's current technical weakness may offer entry points for long-term investors seeking quality insurance exposure with strong ROE of 21.48%.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Cincinnati Financial Corporation
Cincinnati Financial Corp is a property and casualty insurance company that generates income through written premiums. A select group of independent agencies actively markets the company's business, home, and automotive insurance within their communities. These agents offer the company's personal lines as well as its standard market, excess, and surplus commercial line policies in many regions in the United States. Cincinnati Financial also offers leasing and financing services. The vast majority of the company's revenue is generated through commercial lines, followed by personal lines.
Read more on CINF →
